Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

30 October 1998

Cardiovascular agents in renal diseases

Zofia Wańkowicz

Med Sci Monit 1998; 4(6): RA1104-1110 :: ID: 501946

Abstract

Cardiovascular diseases are main, potentially lethal, complications of renal diseases. When using cardiovascular drugs, one should take into consideration the following factors:
- the close cause-effect relationship between cardiac and renal diseases.
- polymorphism of cardiologic complications.
- multiple 'nephrogenic' factors that determine the occurrence of cardiologic complications and their resistance towards standard cardiologic agents. These factors include: hyperkaliemia and hypokaliemia, hypercalcemia and hypocalcemia, hypomagnesemia, metabolic acidosis;
- nephrogenic anemia, secondary hyperparathyroidism, lipid disturbances, hypoproteinemia, coexistent liver damage;
- modifying effect of uremia and dialysis therapy on the pharmacodynamics of cardiologic drugs.Since an ideal cardiological agent is unavailable and the correlation between renal elimination of cardiac drugs and the rate of glomerular filtration remains approximate, cardiac drug doses should be chosen individually, depending on the patients hemodynamic condition, degree of renal failure, evidence of drug cumulation and its blood concentration level. One of the tables is attached, presents cardiac drugs which may be given to patients with renal failure following maintenance dose modification. It is also worth mentioning that cardiac drugs should be administered in full saturating doses in patients with renal failure, and maintenance doses should be modified in such a way as to ensure a stable drug blood level. This may be achieved by reduction of single doses instead of time gap prolongation between standard doses. This study presents a review of cardiovascular drugs taking into consideration their potential benefits as well as potential renal damage with special reference towards: inotropic drugs, antiarrhythmic drugs, adenosine (Adenocor), ACE inhibitors, nitrates, antiplatelet and fibrinolytic drugs, as well as new cardioprotective agents. Presented here, are case reports of successfully treated severe cardiovascular complications in patients with renal failure.

Keywords: renal failure, Dialysis, Cardiovascular Agents

0 Comments

Editorial

15 August 2022 : Editorial  

Editorial: The Metabolic (Dysfunction) Associated Fatty Liver Disease (MAFLD)-Non-Alcoholic Fatty Liver Disease (NAFLD) Debate: A Forced Consensus and The Risk of a World Divide

Nahum Méndez-Sánchez, Ming-Hua Zheng, Takumi Kawaguchi, Shiv K. Sarin
Liver Research Unit, Medica Sur Clinic & Foundation and Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico

DOI: 10.12659/MSM.938080

Med Sci Monit 2022; 28:e938080

In Press

12 Aug 2022 : Clinical Research  

Risk Factors and Pathogen Spectrum in Continuous Ambulatory Peritoneal Dialysis-Associated Peritonitis: A S...

Med Sci Monit In Press; DOI: 10.12659/MSM.937112  

11 Aug 2022 : Meta-Analysis  

Optimal Surgical Treatment Method for Anterior Cruciate Ligament Rupture: Results from a Network Meta-Analysis

Med Sci Monit In Press; DOI: 10.12659/MSM.937118  

10 Aug 2022 : Review article  

Programmed Cell Death in Diabetic Nephropathy: A Review of Apoptosis, Autophagy, and Necroptosis

Med Sci Monit In Press; DOI: 10.12659/MSM.937766  

10 Aug 2022 : Database Analysis  

Use and Effects of Augmentation of Labor with Oxytocin: A Single-Center, Retrospective, Case-Control Study ...

Med Sci Monit In Press; DOI: 10.12659/MSM.937557  

Most Viewed Current Articles

30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

01 Nov 2020 : Review article  

Long-Term Respiratory and Neurological Sequelae of COVID-19

DOI :10.12659/MSM.928996

Med Sci Monit 2020; 26:e928996

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750